Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Income from Continuing Operations rose 173515.06% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 737.56%. This contributed to the annual value of -$4.0 million for FY2024, which is 10749.18% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Income from Continuing Operations stood at $117.3 million, which was up 173515.06% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Income from Continuing Operations ranged from a high of $117.3 million in Q3 2025 and a low of -$51.9 million during Q2 2024
  • Over the past 5 years, Ligand Pharmaceuticals' median Income from Continuing Operations value was $9.6 million (recorded in 2022), while the average stood at $10.6 million.
  • In the last 5 years, Ligand Pharmaceuticals' Income from Continuing Operations tumbled by 236685.59% in 2024 and then surged by 173515.06% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Income from Continuing Operations (Quarter) stood at $13.8 million in 2021, then crashed by 205.33% to -$14.5 million in 2022, then skyrocketed by 225.14% to $18.2 million in 2023, then plummeted by 270.93% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
  • Its Income from Continuing Operations was $117.3 million in Q3 2025, compared to $4.8 million in Q2 2025 and -$42.5 million in Q1 2025.